Biomarin Pharmaceutical Inc
BMRN: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $52.00 | Bqjmzh | Dhnfzwc |
BioMarin's Diversified Rare Disease Business Supports a Narrow Moat
/s3.amazonaws.com/arc-authors/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
Business Strategy and Outlook
BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development expenses kept BioMarin in the red for years despite multiple approved products, but we're confident in the sustainable, profit-generating power of its current portfolio. With a deep in-house pipeline and the ability to supplement growth with strategic acquisitions, BioMarin is in a strong position.